Syros Pharmaceuticals stock plunges to 52-week low of $0.16

In a stark reflection of the challenges facing the biotech sector, Syros Pharmaceuticals Inc . (NASDAQ:SYRS) stock has tumbled to a 52-week low, reaching a distressing price level of just $0.16. According to InvestingPro data, the company’s financial health score is rated as WEAK, with concerning metrics including negative EBITDA of -$110.18M. This latest price point underscores a precipitous decline for the company, which has seen its stock value erode by an alarming 97.85% over the past year. Investors have been grappling with a series of setbacks, including clinical trial uncertainties and a broader market shift away from risk-heavy biotech investments. The dramatic drop to this year’s low highlights the volatility inherent in the pharmaceutical industry, particularly for companies in the drug development stage, and raises concerns about Syros’s future prospects. While the company maintains a current ratio of 2.25, indicating sufficient liquid assets to meet short-term obligations, InvestingPro analysis reveals the company is quickly burning through cash, with upcoming earnings scheduled for March 6th. For deeper insights into SYRS’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.

In other recent news, Syros Pharmaceuticals has been notified of non-compliance with several Nasdaq Global Select Market listing requirements, potentially risking the delisting of its common stock. The company received deficiency letters indicating that the bid price of its common stock has been below the $1.00 minimum requirement, and its Market Value of Listed Securities and Market Value of Publicly Held Shares have not met requisite thresholds for consecutive business days. To avoid delisting, Syros must regain compliance by July 7, 2025, by meeting these thresholds for ten consecutive business days within a 180-day grace period. In another development, Syros Pharmaceuticals has entered into a forbearance agreement with Oxford Finance LLC following a default event related to its clinical trial results. This agreement was necessary after the failure of the SELECT-MDS-1 Phase 3 trial, which led to a demand for immediate repayment of approximately $43.7 million. Under the new loan amendment, Oxford will refrain from enforcing its rights against Syros until February 28, 2025, provided certain conditions are met. Syros is required to adhere to several conditions, including asset sales and operating under a wind-down budget approved by Oxford. These developments mark critical steps for Syros as it addresses financial challenges and aims for resolution by early 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.